췌장암에서 영양 치료 = Nutritional Support for Patients with Pancreatic Cancer

다국어 초록 (Multilingual Abstract)

Pancreatic cancer is the ninth common malignancy in South Korea. It has a dismal prognosis with a 5-year overall survival rate of less than 10%, and pancreatic cancer is associated with cancer cachexia, which is defined as the loss of muscle mass that is not reversible by conventional nutritional support. Cachexia is noted in over 85% of all pancreatic cancer patients and it is strongly related with the disease’s mortality. Nearly 30% of pancreatic cancer deaths are due to cachexia rather than being due to the tumor burden. Therefore, it is crucial to discover the mechanisms behind the development of muscle wasting in pancreatic cancer patients and find novel therapeutics for targeting cachexia. This review deals with the current understanding about the development of cachexia and nutritional support in those patients suffering with pancreatic cancer.

참고문헌 (Reference)

1 Davidson W, "Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer" 23 : 239-247, 2004

2 Loh KW, "Unintentional weight loss is the most important indicator of malnutrition among surgical cancer patients" 70 : 365-369, 2012

3 Lucas DJ, "Trends and risk factors for transfusion in hepatopancreatobiliary surgery" 18 : 719-728, 2014

4 Giovannucci E, "The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas" 132 : 2208-2225, 2007

5 Hackert T, "The pancreas : causes for malabsorption" 30 : 190-197, 2014

6 Abbott CR, "The inhibitory effects of peripheral administration of peptide YY(3-36)and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway" 1044 : 127-131, 2005

7 Klek S, "The immunomodulating enteral nutrition in malnourished surgical patients-a prospective, randomized, double-blind clinical trial" 30 : 282-288, 2011

8 Calnan DR, "The FoxO code" 27 : 2276-2288, 2008

9 Greco SH, "TGF-β blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia" 10 : e0132786-, 2015

10 Farren MR, "Systemic immune activity predicts overall survival in treatment-naïve patients with metastatic pancreatic cancer" 22 : 2565-2574, 2016

11 Sartori R, "Smad2 and 3 transcription factors control muscle mass in adulthood" 296 : C1248-C1257, 2009

12 Mitsunaga S, "Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer" 108 : 2063-2069, 2013

13 Bonetto A, "STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia" 6 : e22538-, 2011

14 Martignoni ME, "Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia" 11 : 5802-5808, 2005

15 Loumaye A, "Role of activin A and myostatin in human cancer cachexia" 100 : 2030-2038, 2015

16 Zhou W, "Role of NF-kappaB and cytokine in experimental cancer cachexia" 9 : 1567-1570, 2003

17 Zhou X, "Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival" 142 : 531-543, 2010

18 McPherron AC, "Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member" 387 : 83-90, 1997

19 Corish CA, "Protein-energy undernutrition in hospital in-patients" 83 : 575-591, 2000

20 Sikkens EC, "Prospective assessment of the influence of pancreatic cancer resection on exocrine pancreatic function" 101 : 109-113, 2014

21 Pannala R, "Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus" 134 : 981-987, 2008

22 Gibbs J, "Preoperative serum albumin level as a predictor of operative mortality and morbidity : results from the national VA surgical risk study" 134 : 36-42, 1999

23 박준성, "Postoperative Nutritional Effects of Early Enteral Feeding Compared with Total Parental Nutrition in Pancreaticoduodectomy Patients: A Prosepective, Randomized Study" 대한의학회 27 (27): 261-267, 2012

24 Skipworth RJ, "Pathophysiology of cancer cachexia : much more than host-tumour interaction" 26 : 667-676, 2007

25 Pelzer U, "Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study" 10 : 86-, 2010

26 Richter E, "Parenteral nutrition support for patients with pancreatic cancer--improvement of the nutritional status and the therapeutic outcome" 32 : 2111-2118, 2012

27 Hart PA, "Pancreatic polypeptide response to a mixed meal is blunted in pancreatic head cancer associated with diabetes mellitus" 15 : 162-166, 2015

28 Mace TA, "Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner" 73 : 3007-3018, 2013

29 Bachmann J, "Pancreatic cancer related cachexia : influence on metabolism and correlation to weight loss and pulmonary function" 9 : 255-, 2009

30 Kneuertz PJ, "Palliative surgical management of patients with unresectable pancreatic adenocarcinoma : trends and lessons learned from a large, single institution experience" 15 : 1917-1927, 2011

31 Billingsley KG, "Outcome after pancreaticoduodenectomy for periampullary cancer : an analysis from the veterans affairs national surgical quality improvement program" 7 : 484-491, 2003

32 Heller AR, "Omega-3 fatty acids improve liver and pancreas function in postoperative cancer patients" 111 : 611-616, 2004

33 Karagianni VT, "Nutritional status and nutritional support before and after pancreatectomy for pancreatic cancer and chronic pancreatitis" 3 : 348-359, 2012

34 Kanda M, "Nutritional predictors of postoperative outcome in pancreatic cancer" 98 : 268-274, 2011

35 Cooperman AM, "Nutritional and metabolic aspects of pancreatic cancer" 3 : 17-21, 2000

36 Gärtner S, "Nutrition in pancreatic cancer : a review" 2 : 195-202, 2016

37 Illés D, "New-onset type 2 diabetes mellitus--a high-risk group suitable for the screening of pancreatic cancer" 16 : 266-271, 2016

38 Gupta S, "New-onset diabetes and pancreatic cancer" 4 : 1366-1372, 2006

39 Guttridge DC, "NF-kappaB-induced loss of MyoD messenger RNA : possible role in muscle decay and cachexia" 289 : 2363-2366, 2000

40 Miyamoto Y, "Molecular pathways : cachexia signaling-a targeted approach to cancer treatment" 22 : 3999-4004, 2016

41 Melstrom LG, "Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia" 22 : 805-814, 2007

42 La Torre M, "Malnutrition and pancreatic surgery : prevalence and outcomes" 107 : 702-708, 2013

43 Zhang L, "MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia" 139 : 1105-1115, 2013

44 Kraft M, "L-carnitine-supplementation in advanced pancreatic cancer(CARPAN)--a randomized multicentre trial" 11 : 52-, 2012

45 Bonetto A, "JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia" 303 : E410-E421, 2012

46 Arshad A, "Intravenous ω-3 fatty acids plus gemcitabine" 41 : 398-403, 2017

47 Russell ST, "Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein" 1636 : 59-68, 2004

48 Von Hoff DD, "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine" 369 : 1691-1703, 2013

49 Kyle UG, "Increased length of hospital stay in underweight and overweight patients at hospital admission : a controlled population study" 24 : 133-142, 2005

50 Felix K, "Identification of serum proteins involved in pancreatic cancer cachexia" 88 : 218-225, 2011

51 Pop VV, "IL-6 roles-molecular pathway and clinical implication in pancreatic cancer-a systemic review" 181 : 45-50, 2017

52 Sacheck JM, "IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1" 287 : E591-E601, 2004

53 Barker LA, "Hospital malnutrition : prevalence, identification and impact on patients and the healthcare system" 8 : 514-527, 2011

54 Augustin T, "Frailty predicts risk of life-threatening complications and mortality after pancreatic resections" 160 : 987-996, 2016

55 Nussbaum DP, "Feeding jejunostomy tube placement in patients undergoing pancreaticoduodenectomy : an ongoing dilemma" 18 : 1752-1759, 2014

56 Imaoka H, "Evaluation of modified glasgow prognostic score for pancreatic cancer : a retrospective cohort study" 45 : 211-217, 2016

57 Liu C, "Enteral nutrition is superior to total parenteral nutrition for pancreatic cancer patients who underwent pancreaticoduodenectomy" 20 : 154-160, 2011

58 Park JW, "Effects of pancreatectomy on nutritional state, pancreatic function and quality of life" 100 : 1064-1070, 2013

59 Wigmore SJ, "Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer" 36 : 177-184, 2000

60 Fearon KC, "Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia : a randomised double blind trial" 52 : 1479-1486, 2003

61 Roeyen G, "Diabetes mellitus and pre-diabetes are frequently undiagnosed and underreported in patients referred for pancreatic surgery. A prospective observational study" 16 : 671-676, 2016

62 Fearon K, "Definition and classification of cancer cachexia : an international consensus" 12 : 489-495, 2011

63 Koutsounas I, "Current evidence for histone deacetylase inhibitors in pancreatic cancer" 19 : 813-828, 2013

64 Di Carlo V, "Complications of pancreatic surgery and the role of perioperative nutrition" 16 : 320-326, 1999

65 Lindkvist B, "Clinical, anthropometric and laboratory nutritional markers of pancreatic exocrine insufficiency : prevalence and diagnostic use" 15 : 589-597, 2015

66 Wigmore SJ, "Changes in nutritional status associated with unresectable pancreatic cancer" 75 : 106-109, 1997

67 Stewart GD, "Cancer cachexia and fatigue" 6 : 140-143, 2006

68 Fearon KC, "Cancer cachexia : mediators, signaling, and metabolic pathways" 16 : 153-166, 2012

69 Ramos EJ, "Cancer anorexia-cachexia syndrome : cytokines and neuropeptides" 7 : 427-434, 2004

70 Bachmann J, "Cachexia worsens prognosis in patients with resectable pancreatic cancer" 12 : 1193-1201, 2008

71 Fearon KC, "Cachexia in pancreatic cancer: new treatment options and measures of success" 12 : 323-324, 2010

72 Argilés JM, "Cachexia and sarcopenia : mechanisms and potential targets for intervention" 22 : 100-106, 2015

73 Mueller TC, "Cachexia and pancreatic cancer : are there treatment options" 20 : 9361-9373, 2014

74 Evans WJ, "Cachexia : a new definition" 27 : 793-799, 2008

75 Gianotti L, "Artificial nutrition after pancreaticoduodenectomy" 21 : 344-351, 2000

76 Kim SY, "Apolipoprotein C-II is a novel substrate for matrix metalloproteinases" 339 : 47-54, 2006

77 Uomo G, "Anorexia-cachexia syndrome in pancreatic cancer : recent development in research and management" 7 : 157-162, 2006

78 Ronga I, "Anorexia-cachexia syndrome in pancreatic cancer : recent advances and new pharmacological approach" 59 : 1-6, 2014

79 Metter EJ, "Age-associated loss of power and strength in the upper extremities in women and men" 52 : B267-B276, 1997

80 Schmitt TL, "Activity of the Akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia" 85 : 647-654, 2007

81 Chen YG, "Activin signaling and its role in regulation of cell proliferation, apoptosis, and carcinogenesis" 231 : 534-544, 2006

82 Togashi Y, "Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer" 356 (356): 819-827, 2015

83 Denley SM, "Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma" 17 : 887-898, 2013

84 Avan A, "AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients" 9 : e108057-, 2014

85 Sikkens EC, "A prospective assessment of the natural course of the exocrine pancreatic function in patients with a pancreatic head tumor" 48 : e43-e46, 2014

86 Fogelman DR, "A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients" 25 : 1809-1817, 2017

87 Vashi PG, "A longitudinal study investigating quality of life and nutritional outcomes in advanced cancer patients receiving home parenteral nutrition" 14 : 593-, 2014